Adding talazoparib to enzalutamide significantly improves the outcomes of untreated patients with metastatic castration-resistant prostate cancer, regardless of homologous recombination repair mutation status, shows the TALAPRO-2 trial.

Phase 2 study data show that the PARP inhibitor talazoparib has antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer bearing DNA damage response alterations in genes associated with homologous recombination repair.

Jennifer Litton discusses results of the NEOTALA trial suggesting patients with germline BRCA1/2-mutant, HER2-negative, early breast cancer may benefit from neoadjuvant treatment with talazoparib.

Talazoparib does not extend overall survival compared with a physician’s choice of chemotherapy, shows the EMBRACA trial of HER2-negative locally advanced and metastatic breast cancer patients with a germline BRCA1/2 mutation.

The regulatory body has also approved an accompanying diagnostic test – the BRACAnalysis CDx test (Myriad Genetics, Salt Lake City, Utah, USA) – to be used to identify patients eligible for talazoparib therapy.

The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1 / 2 mutation.

This translated to a significant association between PARP inhibitor use and pancytopenia for the drug class as a whole (reporting odds ratio [ROR]=5.5) and for the five individual PARP inhibitors assessed, namely talazoparib (ROR=17.4), veliparib (ROR=8.2), niraparib (ROR=6.8), olaparib (ROR=5.3), and rucaparib (ROR=2.2).

JAVELIN PARP Medley: Ongoing   Phase 1b/2 Patient population: Locally advanced or metastatic solid tumors Treatment: Avelumab plus talazoparib at various dose levels Sponsor: Pfizer https://clinicaltrials.gov/ct2/show/NCT03330405 This trial is investigating the antitumor activity and safety of avelumab in combination with the PARP inhibitor talazoparib in patients with locally advanced or metastatic solid tumors, including NSCLC.

“Our results are consistent with those from other studies demonstrating the clinical activity of PARP inhibitors (olaparib, niraparib, and talazoparib) in patients with mCRPC and a BRCA alteration who received prior AR-directed therapy,” say Abida and colleagues.

. © 2019 Springer Healthcare part of the Springer Nature group J Clin Oncol 2019; doi:10.1200/JCO.18.02236 See also: Lorlatinib shows promising activity against ALK-positive advanced NSCLC Lorlatinib given European NSCLC approval Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

. © 2019 Springer Healthcare part of the Springer Nature group See also: Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab PD-L1 diagnostics approved for pembrolizumab, atezolizumab use in urothelial cancer Avelumab, pembrolizumab indications expanded

Related news story: Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab April 2019 saw the approval of pembrolizumab for the first-line treatment of stage III NSCLC that is not amenable to resection or chemoradiotherapy, lacks EGFR or ALK alterations, and has a PD-L1 TPS of 1% or higher.